Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2015 21 419 M
EBIT 2015 8 922 M
Net income 2015 1 444 M
Debt 2015 33 020 M
Yield 2015 -
Sales 2016 24 821 M
EBIT 2016 11 545 M
Net income 2016 4 569 M
Debt 2016 30 984 M
Yield 2016 -
PER 2015 39,18
PER 2016 21,15
EV / Sales 2015 7,13x
EV / Sales 2016 6,07x
Capitalization 119 641 M
More Financials
Company
Actavis plc operates as an investment holding company.It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products.The company operates through the following segments: North... 
Sector
Pharmaceuticals
Calendar
05/11Earnings Release
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
04/24 ACTAVIS : Announces Topline Phase 3 Clinical Trial Results for Single-Dose DALVA..
04/23DJAT&T Looks To Bond Market For DirecTV Deal
04/23 ACTAVIS : Launches AVYCAZ(TM) (Ceftazidime-Avibactam) Anti-Infective In U.S.
04/22DJMeet Pharma's Newest Movers and Shakers, Driving M&A
04/22DJMeet Pharma's Newest Movers and Shakers, Driving M&A
04/22 ACTAVIS : Entry into a Material Definitive Agreement, Creation of a Direct Finan..
04/22 Teva ready to divest operations to win regulatory nod for Mylan buy
04/21 Top Mylan shareholders seek deal with Teva - sources
More news
Sector news : Pharmaceuticals - NEC
04:07a MERCK KGAA : Wins German Innovation Award with Liquid Crystals
01:01a GILEAD SCIENCES : Announces Results From Studies Evaluating Sofosbuvir-Based Reg..
04/24 AKORN : EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities C..
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF